Davies Scott M sold $111K of ILMN

Davies Scott M (Chief Legal Officer) sold 615 shares of ILLUMINA, INC. (ILMN) at $180.00 ($0.11M total) on 2026-06-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Davies Scott M
Published Jun 26, 2026, 1:41 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 26, 2026, 2:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ILMN
Neutral
high confidence
Mentioned
$ILMN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ILMNNeutralLow
01

Why it matters

The newest fact is the specific sale: 615 shares at $180/share ($110,700 total) by the Chief Legal Officer on 2026-06-25 under a 10b5-1 plan.

02

Market read

Primarily useful for sentiment/positioning checks; it does not introduce new operational, financial, or regulatory information.

03

What to watch

The transaction size is small relative to typical institutional flows, and the pre-arranged plan reduces interpretability versus discretionary selling.

Relevance 3/10Novelty 2/10Timing: after-hours/filing update on 2026-06-25 (filed 2026-06-25T21:41:44-04:00)

Background

This is an SEC Form 4 insider transaction disclosure for Illumina, Inc. (ILMN).

Company-level read

Ticker impact

$ILMNNeutralHigh confidence
Context

Illumina Form 4 shows CLO Davies Scott M sold 615 shares at $180 on 2026-06-25 under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any impact is likely limited to intraday sentiment around the filing.

Evidence & confidence

The filing is an open-market sale by an officer under a pre-arranged 10b5-1 plan, with modest share count and no accompanying company-specific operational/regulatory news.

Market effects

No direct read-through to biotech/genomics sector fundamentals; this is company-specific insider transaction data.

Minimal; US-listed large-cap insider sale with no broader market linkage.

None expected beyond routine sentiment monitoring for ILMN.

Counterpoint

Even 10b5-1 sales can coincide with private information, so traders may still watch for follow-on disclosures or unusual volume/price action.

Key entities

  • Illumina, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Davies Scott M

    Chief Legal Officer who sold 615 shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ILMNMed

Illumina selected to help bring precision medicine into everyday healthcare in Singapore

Illumina (ILMN) was selected for the SG-INSIGHT study, part of Singapore's National Precision Medicine program, to provide whole-genome sequencing for 450,000 residents. The study aims to integrate genomic data with healthcare to tailor treatments. Illumina will operate through its local facility, complying with Singapore's regulations. This follows their support in the previous phase of the program.

$ILMNHighAI 9/10

What Sent Illumina Stock Lower?

Illumina (ILMN) stock dropped 18.6% on October 30, 2026, despite beating earnings estimates and raising its full-year revenue outlook. The decline followed a mixed Q3 report where revenue missed estimates due to tariff refunds. Management cited strong sequencing consumables sales and NovaSeq X instrument placements. The broader market also fell, with AI-related stocks underperforming.

$ILMNHighAI 8/10

[Illumina Q3 2026 Earnings Call] Illumina Raises Full-Year Guidance to $4.64–$4.66 Billion as NovaSeq X Placements Top 80 and EPS Hits $1.44

Illumina reported Q3 2026 revenue of $1.17B, up 4.7% YoY, and EPS of $1.44. The company raised full-year guidance to $4.64–$4.66B, citing strong clinical demand and NovaSeq X placements. Operating margin was 25%, 100 bps ahead of guidance. Illumina expects 4.5% organic growth in Q4 and high-single-digit growth for 2027.